RE:RE:Resistance to ADCs in the treatment of solid tumors Presently there is no standardized consensus regarding the optimal management of patients experiencing resistance to ADCs, in particular T-DXd, and clinical trial referral being often considered the best approach, if feasible. Combinatorial strategies with registered regimens are envisaged, especially upon identification of patients’ population of interest with unmet medical needs, and a pelareorep + nab-paclitaxel breast cancer Phase 3 registration study in ADC failed patient,s should lead to a long-anticipated approval of pelareorp, which would then lend support to the above mentioned combinational strategies with registered regimens.